Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. - Wikidata - awgldk - TriplyDB

Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer.

Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer.

http://www.wikidata.org/entity/Q34336386

about

Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes Trial watch - inhibiting PARP enzymes for anticancer therapy The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways Itraconazole, a commonly used antifungal, inhibits Fcγ receptor-mediated phagocytosis: alteration of Fcγ receptor glycosylation and gene expression Recent advances in drug repositioning for the discovery of new anticancer drugs Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent The Repurposing Drugs in Oncology (ReDO) Project.Combination therapy in combating cancer.Highly adaptable triple-negative breast cancer cells as a functional model for testing anticancer agents.Itraconazole suppresses the growth of glioblastoma through induction of autophagy: involvement of abnormal cholesterol trafficking.Identification of an old antibiotic clofoctol as a novel activator of unfolded protein response pathways and an inhibitor of prostate cancer.CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent.A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonism Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again.Antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells.Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.Drug combination therapy increases successful drug repositioning.Itraconazole induces apoptosis and cell cycle arrest via inhibiting Hedgehog signaling in gastric cancer cells.Drug repurposing in oncology--patient and health systems opportunities.Repurposing itraconazole as an anticancer agent.Itraconazole therapy in a pancreatic adenocarcinoma patient: A case report.Repurposing itraconazole for the treatment of cancer.Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent Pharmacological blockade of cholesterol trafficking by cepharanthine in endothelial cells suppresses angiogenesis and tumor growth.Simultaneous Targeting of NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and Angiogenesis.Metronomic chemotherapy remodel cancer-associated fibroblasts to decrease chemoresistance of gastric cancer in nude mice.Successful treatment of oral itraconazole for infantile hemangiomas: a case series.Drug Repositioning for Effective Prostate Cancer Treatment.Itraconazole treatment of primary malignant melanoma of the vagina evaluated using positron emission tomography and tissue cDNA microarray: a case report.

P2860

Q26745422-939CE191-4013-4585-8576-18927E4A795D Q26745673-898DD9A3-638B-44EA-A95D-B932F4F9A988 Q33424852-4F978A28-09CC-4FA4-A04E-448E3ADEDBAA Q33709769-4620E5D3-29C1-4766-BEEE-5F8384CC08B6 Q33810233-752B6808-5128-4386-A909-326DDBE3986D Q33845068-0F1C1D7E-9350-4C7E-AD5F-7998223C893C Q33893928-AD1862A9-0F6A-447E-B092-B15CCB2C88CA Q33893949-24EACD7B-D2A2-4C4E-9CD8-E0A33C580E93 Q33914234-63D663C2-CCC9-46B1-BE5E-6B1D25A927BE Q34287510-38AAC52C-9382-42CB-BE3C-113EC67F12FD Q34373100-E85F7F66-B381-4606-A02E-04BD8AF3632E Q34402836-2DA09185-8392-4628-99DB-A452FD6BDD6A Q34437996-A5500187-23EC-49BE-AF88-C3BE883073F8 Q34474583-5D7AE043-29D7-4790-8C0B-F15AECF9B694 Q34483485-6F24E150-0867-42EA-83AD-904EB71F5B69 Q35252021-88E48426-57B9-4EFF-821F-298EA9C790D8 Q35748908-49154E59-19F7-4948-9691-8967A019FFE7 Q35915762-C1A9655A-CD9E-409B-A42E-DD0B8A22DBD7 Q36435334-C607B4C1-DC6A-4F06-BD6B-A3CD61FD2927 Q36917768-3F486706-B6A7-47BD-A464-85FEEA866333 Q37004251-6281D4CB-7EF5-4028-8AA7-ADE173EE3B59 Q37747533-8D8A6370-E73C-4436-A6D6-B26BB8245917 Q38611707-D57F7E1B-3463-445F-8F13-CA4AAC9B9F17 Q38633691-209716E3-CC50-49E0-9F9F-CC741C5732EC Q41491252-3CC065A7-3A9C-427E-A5C6-B7871CE37B5A Q41613808-3073D63A-B252-4870-B797-6428E929F091 Q41668110-6B22BF2F-7905-46A9-B4D7-0CA99464BA7C Q47783148-06A63B2F-2E43-4500-808B-E381F6855BE5 Q48333797-A989248A-2DD8-4D34-B44B-01E71831451D Q49520667-3DFDB2EE-D384-45B7-BF33-F0CE1E3BC76C Q50455233-EB99BD90-68C5-4BF0-9970-24558A869851 Q55254671-1ED63FA1-1ADE-4E8D-943B-0899909F18D0 Q55489012-8FF2677B-8323-4671-9A4E-46583289F6C4

P2860

Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer.

http://www.wikidata.org/entity/Q34336386

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Phase 2 study of pemetrexed an ...... us non-small-cell lung cancer.

@ast

Phase 2 study of pemetrexed an ...... us non-small-cell lung cancer.

@en

Phase 2 study of pemetrexed an ...... us non-small-cell lung cancer.

@nl

type

label

Phase 2 study of pemetrexed an ...... us non-small-cell lung cancer.

@ast

Phase 2 study of pemetrexed an ...... us non-small-cell lung cancer.

@en

Phase 2 study of pemetrexed an ...... us non-small-cell lung cancer.

@nl

prefLabel

Phase 2 study of pemetrexed an ...... us non-small-cell lung cancer.

@ast

Phase 2 study of pemetrexed an ...... us non-small-cell lung cancer.

@en

Phase 2 study of pemetrexed an ...... us non-small-cell lung cancer.

@nl

P1433

Q34336386-F7B2CA94-D42E-4A7B-8E6D-DC860146A4D0

P1476

Q34336386-6D0FB455-6ACE-43A9-AD7E-58F6823DF827

P2093

Q34336386-0D49A4B3-E26D-4D00-AC5D-F250DCC7B958

Q34336386-3114EFE7-75BE-49BD-BD34-ADCF2607B1D4

Q34336386-5C9B7F38-1018-4076-86B9-825B24CD3037

Q34336386-9FE22F7B-4F02-4633-91C8-E2ACFEB2D30A

Q34336386-AA09E240-FF8E-4C47-8136-932DE20CE2C0

Q34336386-B44CDEEA-D822-46B9-9D72-53D4D78249FD

Q34336386-BFE3CBE0-DCF6-479C-9778-667B27574235

Q34336386-C269939C-1E7A-42CA-99FA-DE827473866B

Q34336386-DCF4B94E-1723-46F7-A53D-45A6032C3958

Q34336386-F89A7B03-6394-4982-9A65-4DD60E506865

P2860

Q34336386-0603C2D5-2A00-4D54-8CAD-42A2E5DBF511

Q34336386-4F3F6F3C-507C-4C1E-9842-927FC8EB3884

Q34336386-61E729E2-15C9-4C86-BF0E-067AAAD4F824

Q34336386-67D4831A-D813-453F-A087-AF72FB747636

Q34336386-69382EB1-BC62-4A1E-8ACA-43E1922CCCCF

Q34336386-6A866D48-4A12-491F-A8DB-F17DC4F8011D

Q34336386-8EDD3220-9965-468C-A741-F6B5D63D126F

Q34336386-99C647FF-1A7C-45CA-AAC6-BEC0330F06CB

Q34336386-C8D7D839-C454-417A-9C2B-EDF1091413B4

Q34336386-C9BE776C-E755-4C9A-B67B-D4E5E901F847

P304

Q34336386-95C08EF6-9EF5-4DAC-92B6-CD3786DD19A7

P31

Q34336386-234180F4-DC68-4EDC-8810-702944086D3D

P356

Q34336386-58CCE22C-A0B1-4147-8307-5330A05BB0F1

P433

Q34336386-0D5D6F99-F399-4C9F-88B3-474D2F85D6CD

P478

Q34336386-DE76B96F-4D99-44D6-9DC8-1EF56752E5A4

P577

Q34336386-CED69EA8-D0CD-410A-8747-49CF79C6FDB3

P698

Q34336386-91EA9123-FABE-4F77-8B27-EE5FA3288393

P932

Q34336386-9C440F57-8E92-4D0A-8772-DB84830C0F96

P356

JTO.0B013E31828C3950

P1433

Journal of Thoracic Oncology

P1476

Phase 2 study of pemetrexed an ...... us non-small-cell lung cancer.

@en

P2093

Blake T Aftab

http://www.w3.org/2001/XMLSchema#string

Charles M Rudin

http://www.w3.org/2001/XMLSchema#string

Christine L Hann

http://www.w3.org/2001/XMLSchema#string

David S Ettinger

http://www.w3.org/2001/XMLSchema#string

Julie R Brahmer

http://www.w3.org/2001/XMLSchema#string

Jun O Liu

http://www.w3.org/2001/XMLSchema#string

Peng Huang

http://www.w3.org/2001/XMLSchema#string

Rosa Sebree

http://www.w3.org/2001/XMLSchema#string

Rosalyn A Juergens

http://www.w3.org/2001/XMLSchema#string

Ruth Smith

http://www.w3.org/2001/XMLSchema#string

P2860

Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer

Cancer statistics, 2010

Cancer statistics, 2012

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Inhibition of angiogenesis by the antifungal drug itraconazole.

Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis.

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer.

P304

619-623

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/JTO.0B013E31828C3950

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23546045

http://www.w3.org/2001/XMLSchema#string

P932

3636564

http://www.w3.org/2001/XMLSchema#string